Products Description
English name:Calicheamicin
CAS number:108212-75-5
Molecular formula: C55H74IN3O21S4
Molecular weight: 1,368.34
EINECS No:
Related categories: API [for scientific research only]; pharmaceutical API; scientific research active drug series; API; API and intermediates; reagents; others; chemical reagents; ADC; Pharmaceutical
The Mol file: 108212-75-5.mol
Molecular structure:

Calithromycin properties
Specific rotation: D26-124 (c = 0.98%, EtOH)
Density: 1.57 ± 0.1 g/cm3 (Predicted)
Storage conditions: Store at-20 C
Solubility: DMSO: 100 mg/mL (73.08 mM); water: <0.1 mg / mL (insoluble)
Form: solid
Aciity coefficient (pK a): 7.13 ± 0.60 (Predicted)
Color: White to yellow
Use and synthesis method of Calicimamycin
Brief introduction
calicheamicins (CLM) is an enediyne anti-tumor antibiotic isolated from the fermentation broth of rare small monosporum.
Mechanism of action
The bioactive concentration of carchithromycin <1 PgmL-1 had extremely potent killing effects in leukemia such as lymphocytic leukaemia P388 and L1210 cells as well as solid tumors such as colon cancer 26 and melanoma B-16 cells. The biological activity of cazithromycin mainly by combining cellular DNA with the Chemicalbook minor groove, directly break cell DNA, further induce tumor cell apoptosis, at the same time, cazithromycin has nonspecific damage effect on cellular RNA, Mylotarg with CD33 monoclonal antibody conjugate is the first approved by the FDA for tumor treatment, has been used in clinical practice.
Use
Cchithromycin is a potent cytotoxic agent that can cause DNA double strand breaks.
Toxicity
Cachithromycin is highly toxic and is one of hundreds of metabolites produced by soil bacteria.
Bioactivity
Calicheamicin Is a tumor antibiotic and also a potent cytotoxic agent, causing DNA double-strand breaks. Calicheamicin Inhibition of DNA synthesis.
Target spot
Calicheamicins
In vitro study
PF-06647263(anti-EFNA4-ADC)isgeneratedviaconjugationofhE22lysineresiduestotheAcButDMH-N-Ac-calicheamicin-γ1linker-payloadwithanaveragedrug-to-antibodyratio(DAR)of4.6.PF-06647263elicitsantigen-andconcentration-dependentcytotoxicity,asexposuretoPF-06647263for96hoursresultsincelldeath(EC50=appr1ng/mL).CMC-544,consistingofahumanizedCD22Ablinkedtocalicheamicin,iseffeChemicalbookctiveinpediatricprimaryB-cellprecursoracutelymphoblasticleukemia(BCP-ALL)cellsinvitro.CMC-544inducescelldeathinvariousALLcelllinesinadose-andtime-dependentway,withIC50valuesrangingfrom0.15to4.9ng/mL.CMC-544(10ng/mL)iseffectiveandspecificinprimaryBCP-ALLcells.InCMC-544-treatedcells,thelevelofCD22hasdecreasedrelativetothatonG5/44-treatedcellsandcontinuedtodecrease.
In vivo research
AnADCcomprisingahumanizedanti-EFNA4monoclonalantibodyconjugatedtotheDNA-damagingagentcalicheamicinachievessustainedtumorregChemicalbookressionsinbothTNBCandovariancancerPDXinvivo.PF-06647263(0.27,0.36mg/kg)resultsinsignificanttumorregressionsinTNBCxenografts.
Hot Tags: calicheamicin tumor antibiotic cytotoxic agent, China calicheamicin tumor antibiotic cytotoxic agent suppliers, MC-Val-Cit-PAB, N Acetyl Calicheamicin Highly Active Anti tumor Antibiotic, 146478-72-0, 863971-12-4, Maytasinol, 796073-69-3

